Literature DB >> 25376055

Expanded access to non-VA care through the Veterans Choice Program. Interim final rule.

.   

Abstract

The Department of Veterans Affairs (VA) amends its medical regulations concerning its authority for eligible veterans to receive care from non-VA entities and providers. The Veterans Access, Choice, and Accountability Act of 2014 directs VA to establish a program to furnish hospital care and medical services through non-VA health care providers to veterans who either cannot be seen within the wait-time goals of the Veterans Health Administration or who qualify based on their place of residence (hereafter referred to as the Veterans Choice Program, or the ``Program''). The law also requires VA to publish an interim final rule establishing this program. This interim final rule defines the parameters of the Veterans Choice Program, and clarifies aspects affecting veterans and the non-VA providers who will furnish hospital care and medical services through the Veterans Choice Program.

Mesh:

Year:  2014        PMID: 25376055

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  3 in total

1.  Comparing Driving Miles for Department of Veterans Affairs-delivered Versus Department of Veterans Affairs-purchased Cataract Surgery.

Authors:  Warren B P Pettey; Todd H Wagner; Amy K Rosen; Erin Beilstein-Wedel; Michael Shwartz; Megan E Vanneman
Journal:  Med Care       Date:  2021-06-01       Impact factor: 3.178

2.  Creating a roadmap for delivering gender-sensitive comprehensive care for women Veterans: results of a national expert panel.

Authors:  Miriam deKleijn; Antoine L M Lagro-Janssen; Ismelda Canelo; Elizabeth M Yano
Journal:  Med Care       Date:  2015-04       Impact factor: 2.983

3.  Development and Clinical Evaluation of an mHealth Application for Stress Management.

Authors:  Brent D Winslow; George L Chadderdon; Sara J Dechmerowski; David L Jones; Solomon Kalkstein; Jennifer L Greene; Philip Gehrman
Journal:  Front Psychiatry       Date:  2016-07-26       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.